Search Result

Results for "

SN38

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Cytotoxin (3) ADC Linker (1) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (3) Apoptosis (2) Autophagy (3) Bacterial (1) BCRP (2) Checkpoint Kinase (Chk) (1) Drug Metabolite (3) Drug-Linker Conjugates for ADC (12) EGFR (1) Fatty Acid Synthase (FASN) (1) Fungal (1) GLUT (1) Isotope-Labeled Compounds (1) RET (1) Topoisomerase (9) TROP2 (2) VEGFR (1)
By Research Areas:	Cancer (32) Infection (2) Inflammation/Immunology (1) Metabolic Disease (1)
Click Chemistry:	Azide (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13704

*SN-38* Maximum Cited Publications 41 Publications Verification 7-Ethyl-10-hydroxycamptothecin	Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy	Cancer
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

HY-126373

SN-38 glucuronide SN-38G	Drug Metabolite	Cancer
SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-153962

SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3	Drug-Linker Conjugates for ADC	Cancer
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs . SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

HY-153013

SN38-COOH	Drug-Linker Conjugates for ADC	Cancer
SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis .

HY-13704S

SN-38-d3 NK012-d₃	Topoisomerase ADC Cytotoxin Autophagy	Cancer
SN-38-d₃ is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].

HY-145767A

SN-38-CO-DMEDA TFA	Others	Others
SN-38-CO-DMEDA TFA is the intermediate product for synthesizing antibody-conjugated drug LND1035 .

HY-128943

MAC glucuronide phenol-linked SN-38	Drug-Linker Conjugates for ADC	Cancer
MAC glucuronide phenol-linked SN-38 is a pH-susceptible lactone MAC glucuronide phenol-linked SN-38 (DNA topoisomerase I inhibitor) agent linker. MAC glucuronide phenol-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC₅₀ values of 113 and 67 ng/mL, respectively.Albumin-coupled MAC glucosidol-linked SN-38 shows good stability in mouse plasma .

HY-13704R

SN-38 (Standard)	Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy	Cancer
SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

HY-126373S1

SN-38 glucuronide-13C6 SN-38G-¹³C₆	Isotope-Labeled Compounds	Others
SN-38 glucuronide- ¹³C₆ is the ¹³C labeled SN-38 glucuronide (HY-126373) . SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

HY-157797

SN-38-CM2	Others	Cancer
SN-38-CM2 is a split esterase, and shows >95% conversion to SN-38 within 5 min in vitro. SN-38-CM2 induces protein-protein interactions (PPI)-dependent esterase to mediate cell death in MDA-MB-231 cells .

HY-128942

MAC glucuronide α-hydroxy lactone-linked SN-38	Drug-Linker Conjugates for ADC	Cancer
MAC glucuronide α-hydroxy lactone-linked SN-38 (Topoisomerase I inhibitor) is a stabilized lactone MAC glucuronide α-hydroxy lactone-linked SN-38 agent linker. MAC glucuronide α-hydroxy lactone-linked SN-38 is cytotoxic across L540cy cells and Ramos cells with IC₅₀ values of 99 and 105 ng/mL, respectively .

HY-145513

CL2-MMT-SN38	Topoisomerase	Cancer
CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11) .

HY-164271

10-Boc-SN-38	Topoisomerase	Cancer
10-Boc-SN-38 is a tert-butyloxycarbonyl (Boc)-protected form of SN-38 (HY-13704). SN-38 is the active metabolite of Irinotecan (HY-16562) .

HY-159563

Mal-va-mac-SN38	Drug-Linker Conjugates for ADC	Cancer
Mal-va-mac-SN38 is a drug-linker conjugate for ADC. Mal-va-mac-SN38 contains a ADC cytotoxin SN-38 (HY-13704) and a linker (HY-126364). Mal-va-mac-SN38 can rapidly and covalently bind with endogenous albumin in vivo, resulting in the formation of HSA-va-mac-SN38. Mal-va-mac-SN38 demonstrates exceptional stability in human plasma, and has anti-tumor and anti-metastasis effect .

HY-136170

MC-SN38	Drug-Linker Conjugates for ADC	Cancer
MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks .

HY-131057

Mc-VC-PAB-SN38	Drug-Linker Conjugates for ADC	Cancer
Mc-VC-PAB-SN38 consists a cleavable ADC linker (Mc-VC-PAB) and a DNA topoisomerase I inhibitor (SN38). Mc-VC-PAB-SN38 can be used in the synthesis of antibody-drug conjugates (ADCs) .

HY-139909

CL2E-SN38	Drug-Linker Conjugates for ADC	Cancer
CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .

HY-139909A

*CL2E-SN38* TFA**	Drug-Linker Conjugates for ADC	Cancer
CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .

HY-P99681

Labetuzumab govitecan IMMU 130; hMN-14-SN-38	Antibody-Drug Conjugates (ADCs)	Cancer
Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer .

HY-128946

CL2A-SN-38 2 Publications Verification	Drug-Linker Conjugates for ADC	Inflammation/Immunology Cancer
CL2A-SN-38 is a agent-linker conjugate composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody agent conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A-SN-38 uses hydrolyzable linker to deliver active agents within tumor cells and in the tumor microenvironment, resulting in bystander effects .

HY-155034

Antitumor agent-102	Topoisomerase GLUT	Cancer
Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .

HY-132254

Sacituzumab govitecan 3 Publications Verification IMMU-132	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity .

HY-132254A

Sacituzumab govitecan (solution) 3 Publications Verification IMMU-132 (solution)	Antibody-Drug Conjugates (ADCs) TROP2	Cancer
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity .

HY-14871

Tenifatecan SN2310	Topoisomerase	Cancer
Tenifatecan (SN2310) is an injectable emulsion composed of vitamin E, a succinate derivative, as well as 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan). Tenifatecan (SN2310) possesses anticancer activity .

HY-153395

PH-HG-005-5	Drug-Linker Conjugates for ADC	Cancer
PH-HG-005-5 (compound 16c) is a derivative of SN-38 (HY-13704) and can be used as Drug-Linker Conjugates for ADC. PH-HG-005-5 can conjugate to targeting peptides for ADCs synthesis .

HY-119724

ABCG2-IN-3	BCRP	Cancer
ABCG2-IN-3 (Compound 52) is a selective inhibitor for breast cancer resistance protein (ABCG2), with an IC₅₀ of 0.238 µM. ABCG2-IN-3 reverses the ABCG2-mediated resistance toward SN-38 and inhibit the ATPase activity .

HY-100195

SAR-020106 1 Publications Verification	Checkpoint Kinase (Chk)	Cancer
SAR-020106 is an ATP-competitive, potent, and selective CHK1 inhibitor with an IC₅₀ of 13.3 nM for human CHK1. SAR-020106 shows excellent selectivity over CHK2. SAR-020106 significantly enhances the cell killing of Gemcitabine and SN38 by 3- to 29-fold in several colon tumor lines and in a p53-dependent fashion. SAR-020106 can enhance antitumor activity with selected anticancer agents .

HY-146025

Antitumor agent-F10	Others	Cancer
Antitumor agent-F10 (Compound F10) is a camptothecin derivative. Antitumor agent-F10 is an orally–bioavailable and potent antitumor agent. Antitumor agent-F10 displays lower acute toxicity than SN-38 does and the solubility of F10 reached 9.86 μg/mL .

HY-135845

TP3011 CH0793011	Topoisomerase	Cancer
TP3011 (CH0793011) is an active metabolite of CH-0793076 and is a potent topoisomerase I inhibitor equipotent as SN38 . TP3011 is against cancer cell lines growth with IC₅₀s at the range sub-nanomolar in vitro .

HY-148044

UNC10201652	Bacterial	Infection
UNC10201652 is a potent Loop 1 (L1)-specific gut bacterial β-glucuronidase (GUSs) inhibitor with an IC₅₀ value of 0.117 μM for E. coli GUS. UNC10201652 can block SN-38 glucuronide (HY-126373) processing only in individuals whose fecal gut microbiota is highly abundant in L1 GUS enzymes .

HY-126350

CL2-SN-38	Drug-Linker Conjugates for ADC	Cancer
CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer .

HY-12757

YHO-13177 2 Publications Verification	BCRP	Cancer
YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC₅₀ value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .

HY-164413

CLM3	VEGFR EGFR RET Apoptosis	Cancer
CLM3, a pyrazolopyrimidine derivative, is a multiple tyrosine kinase inhibitor. CLM3 shows antiproliferative and proapoptotic activity on endothelial and cancer cells, synergistically enhanced by SN38 (HY-13704). These effects are mainly due to its inhibition of phosphorylation of VEGFR-2, EGFR and RET tyrosine kinases and their related signaling pathways .

HY-158230

SN-398	Topoisomerase	Cancer
SN-398 is a derivative of Camptothecin (HY-158230), which is an antitumor drug. Acting by inhibiting mammalian DNA topoisomerase I (Topo I), stabilizing the Topo I-DNA complex prevents DNA rewiring to induce Topo I mediated DNA breaks. In Hela cell tests, SN-398 shows stronger antitumor activity than SN-38 (HY-13704) (IC₅₀=1.562 μM). SN-398 can be used to study the anti-proliferation and growth inhibition of Topo I in cancer cells .

HY-128947

CL2 Linker	ADC Linker	Cancer
CL2 Linker is a cleavableADC linker. CL2-SN-38 and CL2A-SN-38 are equivalent in agent substitution (~6), cell binding (K_d ~1.2 nM), cytotoxicity (IC₅₀ ~2.2 nM), and serum stability in vitro (t_1/2 ~20 hours) .

HY-A0210

Cerulenin 5 Publications Verification	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic	Infection Metabolic Disease
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-13704

*SN-38* 40+ Cited Publications 7-Ethyl-10-hydroxycamptothecin	Alkaloids Structural Classification Classification of Application Fields Labiatae Samanea saman (Jacq.) Merr. Source classification Quinoline Alkaloids Plants Disease Research Fields Cancer	Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy
SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC₅₀s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

HY-A0210

Cerulenin 5 Publications Verification	Structural Classification Microorganisms Antifungal Classification of Application Fields Antibiotics Source classification Metabolic Disease Mammalian Cell Culture Disease Research Anticancer Disease Research Fields Other Antibiotics	Fatty Acid Synthase (FASN) Fungal Apoptosis Antibiotic
Cerulenin, a potent, natural inhibitor of fatty acid synthase (FASN), is an epoxide produced by the fungus Cephalosporium caeruleus. Cerulenin inhibits topoisomerase I catalytic activity and augments SN-38-induced apoptosis. Cerulenin has antifungal and antitumor activies .

HY-13704R

SN-38 (Standard)	Alkaloids Structural Classification Labiatae Samanea saman (Jacq.) Merr. Source classification Quinoline Alkaloids Plants	Drug Metabolite Topoisomerase ADC Cytotoxin Autophagy
SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .

Cat. No.	Product Name	Chemical Structure

HY-13704S

SN-38-d3
SN-38-d₃ is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively[1][2][3][4].

HY-126373S1

SN-38 glucuronide-13C6
SN-38 glucuronide- ¹³C₆ is the ¹³C labeled SN-38 glucuronide (HY-126373) . SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81248

	SN38 Antibody (YA923) SN-38 antibody,SN38 antibody	WB, ELISA	Species independent
	SN38 Antibody (YA923) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA923), targeting SN38. SN38 Antibody (YA923) can be used for WB, ELISA experiment in species independent background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-153962

SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3		Azide
SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a Drug-Linker Conjugate for ADC. SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 consists of the anti-cancer agent SN38 (HY-13704) and a linker Lys(MMT)-PAB-oxydiacetamide-PEG8-N3 (HY-131157). SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 can be used for synthesis of ADCs . SN38-PAB-Lys(MMT)-oxydiacetamide-PEG8-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

SN38

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products